Compare ETV & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest
Current Price
| Metric | ETV | PHVS |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | N/A | 2021 |
| Metric | ETV | PHVS |
|---|---|---|
| Price | $14.40 | $26.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $39.44 |
| AVG Volume (30 Days) | 252.5K | ★ 528.8K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 8.75% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.05 | $11.51 |
| 52 Week High | $13.50 | $29.80 |
| Indicator | ETV | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 56.11 | 54.78 |
| Support Level | $14.26 | $23.80 |
| Resistance Level | $14.61 | $29.80 |
| Average True Range (ATR) | 0.20 | 2.25 |
| MACD | 0.03 | 0.19 |
| Stochastic Oscillator | 78.65 | 53.48 |
Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of common stocks, designated segments of which seek to exceed the total return performance of the S&P 500 and the NASDAQ-100.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.